Vanda Pharmaceuticals Inc (NAS:VNDA)
$ 5.04 -0.11 (-2.14%) Market Cap: 293.87 Mil Enterprise Value: -68.03 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 81/100

Q1 2022 Vanda Pharmaceuticals Inc Earnings Call Transcript

May 05, 2022 / 08:30PM GMT
Release Date Price: $9.8 (-4.20%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Quarter 1 2022 Vanda Pharmaceuticals Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would like to turn the call over to our speaker today, Kevin Moran, Vanda's Chief Financial Officer. Sir, you may begin.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Thank you, Marjorie. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' First Quarter 2022 performance. Our first quarter 2022 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihales Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board. Additionally, we have Tim Williams, our General

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot